Russia to supply power to Lugansk Republic after Ukraine cuts electricity — sourceRussian Politics & Diplomacy April 25, 15:15
Kremlin spokesman dismisses cyberattacks allegations against Russia as 'fake news'Russian Politics & Diplomacy April 25, 15:00
OSCE begins internal probe into SMM car blast in DonbassWorld April 25, 14:56
World’s legendary goaltender Vladislav Tretiak turns 65Sport April 25, 14:49
Russian missile frigate holds artillery drills in MediterraneanMilitary & Defense April 25, 14:48
Lavrov slams US ‘Russia-arms-Taliban’ remarks as ‘red herring’ to divert focus from SyriaRussian Politics & Diplomacy April 25, 14:46
Lavrov: Russia’s Aerospace Force maintains security of Russian personnel in SyriaRussian Politics & Diplomacy April 25, 14:07
Lavrov calls for tighter security at OSCE mission in DonbassRussian Politics & Diplomacy April 25, 14:01
China's Huawei to invest $3 mln in joint projects with Russia in 2017Business & Economy April 25, 13:33
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.